Lab focus: Manipulating cell death for cancer therapy
My laboratory aims to manipulate the normal cellular pathways to cell death in order to selectively kill cancer cells.
Focusing on a controlled form of cell death called apoptosis, we seek to find genes or proteins that tumour cells depend upon for growth, thus identifying new therapeutic targets that can inform the design of novel anti-cancer drugs.
Our overarching aim is to facilitate the progression of new targeted drugs into the clinic for the treatment of patients with cancer, in particular blood cell derived cancers.
Find out more about Gemma Kelly's experience
Gemma Kelly's highlights
Gemma Kelly's selected work
EBV BCL-2 homologue BHRF1 drives chemoresistance and lymphomagenesis by inhibiting multipl..
Mutant TRP53 exerts a target gene-selective dominant-negative effect to drive tumor develo..
Displaying the 37 most recent scholarly works by Gemma Kelly.
Potent efficacy of MCL-1 inhibitor-based therapies in preclinical models of mantle cell lymphoma.
Michael A Dengler, Charis E Teh, Rachel Thijssen, Lahiru Gangoda, Ping Lan, Marco J Herold, Daniel H Gray, Gemma L Kelly, Andrew W Roberts, Jerry M Adams
Journal article | 2019 | Oncogene
Apoptosis-regulating BCL-2 family members, which can promote malignant transformation and resistance to therapy, have become prime..
EBV BCL-2 homologue BHRF1 drives chemoresistance and lymphomagenesis by inhibiting multiple cellular pro-apoptotic proteins.
Leah Fitzsimmons, Rachel Cartlidge, Catherine Chang, Nenad Sejic, Laura CA Galbraith, Chathura D Suraweera, Deborah Croom-Carter, Grant Dewson, Rosemary J Tierney, Andrew I Bell, Clare Shannon-Lowe, Marco J Herold, Alan B Rickinson, Peter M Colman, David CS Huang, Andreas Strasser, Marc Kvansakul, Martin Rowe, Gemma L Kelly
Journal article | 2019 | Cell Death & Differentiation
Epstein-Barr virus (EBV), which is ubiquitous in the adult population, is causally associated with human malignancies. Like many i..
VDAC2 enables BAX to mediate apoptosis and limit tumor development
Hui San Chin, Mark X Li, Iris KL Tan, Robert L Ninnis, Boris Reljic, Kristen Scicluna, Laura F Dagley, Jarrod J Sandow, Gemma L Kelly, Andre L Samson, Stephane Chappaz, Seong L Khaw, Catherine Chang, Andrew Morokoff, Kerstin Brinkmann, Andrew Webb, Colin Hockings, Cathrine M Hall, Andrew J Kueh, Michael T Ryan, et al.
Journal article | 2018 | Nature Communications
Mutant TRP53 exerts a target gene-selective dominant-negative effect to drive tumor development
Brandon J Aubrey, Ana Janic, Yunshun Chen, Catherine Chang, Elizabeth C Lieschke, Sarah T Diepstraten, Andrew J Kueh, Jonathan P Bernardini, Grant Dewson, Lorraine A O'Reilly, Lachlan Whitehead, Anne K Voss, Gordon K Smyth, Andreas Strasser, Gemma L Kelly
Journal article | 2018 | Genes & Development
Inhibitors of histone acetyltransferases KAT6A/B induce senescence and arrest tumour growth
Jonathan B Baell, David J Leaver, Stefan J Hermans, Gemma L Kelly, Margs S Brennan, Natalie L Downer, Nghi Nguyen, Johannes Wichmann, Helen M Mcrae, Yuqing Yang, Ben Cleary, H Rachel Lagiakos, Stephen Mieruszynski, Guido Pacini, Hannah K Vanyai, Maria I Bergamasco, Rose E May, Bethany K Davey, Kimberly J Morgan, Andrew J Sealey, et al.
Journal article | 2018 | Nature
Coordinated repression of BIM and PUMA by Epstein-Barr virus latent genes maintains the survival of Burkitt lymphoma cells
Leah Fitzsimmons, Andrew J Boyce, Wenbin Wei, Catherine Chang, Deborah Croom-Carter, Rosemary J Tierney, Marco J Herold, Andrew I Bell, Andreas Strasser, Gemma L Kelly, Martin Rowe
Journal article | 2018 | Cell Death & Differentiation
The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models
Andras Kotschy, Zoltan Szlavik, James Murray, James Davidson, Ana Leticia Maragno, Gaetane Le Toumelin-Braizat, Maia Chanrion, Gemma L Kelly, Jia-Nan Gong, Donia M Moujalled, Alain Bruno, Marton C Sekei, Attila Paczal, Zoltan B Szabo, Szabolcs Sipos, Gabor Radics, Agnes Proszenyak, Balazs Balint, Levente Ondi, Gabor Blasko, et al.
Journal article | 2016 | Nature
MCL-1 is required throughout B-cell development and its loss sensitizes specific B-cell subsets to inhibition of BCL-2 or BCL-XL
Ingela B Vikstrom, Anne Slomp, Emma M Carrington, Laura M Moesbergen, Catherine Chang, Gemma L Kelly, Stefan P Glaser, JH Marco Jansen, Jeanette HW Leusen, Andreas Strasser, David CS Huang, Andrew M Lew, Victor Peperzak, David M Tarlinton
Journal article | 2016 | Cell Death & Disease
BET inhibition represses miR17-92 to drive BIM-initiated apoptosis of normal and transformed hematopoietic cells
Z Xu, PP Sharp, Y Yao, D Segal, CH Ang, SL Khaw, BJ Aubrey, J Gong, GL Kelly, MJ Herold, A Strasser, AW Roberts, WS Alexander, CJ Burns, DCS Huang, SP Glaser
Journal article | 2016 | Leukemia
Re-activation of mitochondrial apoptosis inhibits T-cell lymphoma survival and treatment resistance
S Spinner, G Crispatzu, J-H Yi, E Munkhbaatar, P Mayer, U Hoeckendorf, N Mueller, Z Li, T Schader, H Bendz, S Hartmann, M Yabal, K Pechloff, M Heikenwalder, GL Kelly, A Strasser, C Peschel, M-L Hansmann, J Ruland, U Keller, et al.
Journal article | 2016 | Leukemia
Therapeutic Response to Non-genotoxic Activation of p53 by Nutlin3a Is Driven by PUMA-Mediated Apoptosis in Lymphoma Cells
Liz J Valente, Brandon J Aubrey, Marco J Herold, Gemma L Kelly, Lina Happo, Clare L Scott, Andrea Newbold, Ricky W Johnstone, David CS Huang, Lyubomir T Vassilev, Andreas Strasser
Journal article | 2016 | Cell Reports
The Transcription Factor ASCIZ and Its Target DYNLL1 Are Essential for the Development and Expansion of MYC-Driven B Cell Lymphoma
David M Wong, Lingli Li, Sabine Jurado, Ashleigh King, Rebecca Bamford, Meaghan Wall, Mannu K Walia, Gemma L Kelly, Carl R Walkley, David M Tarlinton, Andreas Strasser, Joerg Heierhorst
Journal article | 2016 | Cell Reports
An Inducible Lentiviral Guide RNA Platform Enables the Identification of Tumor-Essential Genes and Tumor-Promoting Mutations In Vivo
Brandon J Aubrey, Gemma L Kelly, Andrew J Kueh, Margs S Brennan, Liam O'Connor, Liz Milla, Stephen Wilcox, Lin Tai, Andreas Strasser, Marco J Herold
Journal article | 2015 | Cell Reports
Targeting of MCL-1 kills MYC-driven mouse and human lymphomas even when they bear mutations in p53
Gemma L Kelly, Stephanie Grabow, Stefan P Glaser, Leah Fitzsimmons, Brandon J Aubrey, Toru Okamoto, Liz J Valente, Mikara Robati, Lin Tai, W Douglas Fairlie, Erinna F Lee, Mikael S Lindstrom, Klas G Wiman, David CS Huang, Philippe Bouillet, Martin Rowe, Alan B Rickinson, Marco J Herold, Andreas Strasser
Journal article | 2014 | Genes & Development
Different Patterns of Epstein-Barr Virus Latency in Endemic Burkitt Lymphoma (BL) Lead to Distinct Variants within the BL-Associated Gene Expression Signature
Gemma L Kelly, Julianna Stylianou, Jane Rasaiyaah, Wenbin Wei, Wendy Thomas, Deborah Croom-Carter, Christian Kohler, Rainer Spang, Ciaran Woodman, Paul Kellam, Alan B Rickinson, Andrew I Bell
Journal article | 2013 | Journal of Virology
An Epstein-Barr Virus Anti-Apoptotic Protein Constitutively Expressed in Transformed Cells and Implicated in Burkitt Lymphomagenesis: The Wp/BHRF1 Link
Gemma L Kelly, Heather M Long, Julianna Stylianou, Wendy A Thomas, Alison Leese, Andrew I Bell, Georg W Bornkamm, Josef Mautner, Alan B Rickinson, Martin Rowe
Journal article | 2009 | PLOS PATHOGENS
Down-regulation of the TGF-beta target gene, PTPRK, by the Epstein-Barr virus-encoded EBNA1 contributes to the growth and survival of Hodgkin lymphoma cells
Joanne R Flavell, Karl RN Baumforth, Victoria HJ Wood, Gillian L Davies, Wenbin Wei, Gary M Reynolds, Susan Morgan, Andrew Boyce, Gemma L Kelly, Lawrence S Young, Paul G Murray
Journal article | 2008 | BLOOD
Truncated form of the Epstein-Barr virus protein EBNA-LP protects against caspase-dependent apoptosis by inhibiting protein phosphatase 2A.
Julie Garibal, Emilie Hollville, Andrew I Bell, Gemma L Kelly, Benjamin Renouf, Yasushi Kawaguchi, Alan B Rickinson, Joëlle Wiels
Journal article | 2007 | Journal of Virology
The Epstein-Barr virus (EBV)-encoded leader protein, EBNA-LP, strongly activates the EBNA2-mediated transcriptional activation of ..
Methylation status of the Epstein-Barr virus (EBV) BamHI W latent cycle promoter and promoter activity: analysis with novel EBV-positive Burkitt and lymphoblastoid cell lines.
Isabel A Hutchings, Rosemary J Tierney, Gemma L Kelly, Julianna Stylianou, Alan B Rickinson, Andrew I Bell
Journal article | 2006 | Journal of Virology
The Epstein-Barr virus (EBV) latent cycle promoter Wp, present in each tandemly arrayed copy of the BamHI W region in the EBV geno..
Three restricted forms of Epstein-Barr virus latency counteracting apoptosis in c-myc-expressing Burkitt lymphoma cells.
Gemma L Kelly, Anne E Milner, Gouri S Baldwin, Andrew I Bell, Alan B Rickinson
Journal article | 2006 | Proceedings of the National Academy of Sciences
Epstein-Barr virus (EBV), a human herpesvirus, transforms B cell growth in vitro through expressing six virus-coded Epstein-Barr n..
Analysis of Epstein-Barr virus latent gene expression in endemic Burkitt's lymphoma and nasopharyngeal carcinoma tumour cells by using quantitative real-time PCR assays.
Andrew I Bell, Katherine Groves, Gemma L Kelly, Debbie Croom-Carter, Edwin Hui, Anthony TC Chan, Alan B Rickinson
Journal article | 2006 | Journal of General Virology
Studies of Epstein-Barr virus (EBV)-positive cell lines have identified several forms of virus latency, but the patterns of virus ..
Epstein-Barr virus nuclear antigen 2 (EBNA2) gene deletion is consistently linked with EBNA3A, -3B, and -3C expression in Burkitt's lymphoma cells and with increased resistance to apoptosis.
Gemma L Kelly, Anne E Milner, Rosemary J Tierney, Debbie SG Croom-Carter, Markus Altmann, Wolfgang Hammerschmidt, Andrew I Bell, Alan B Rickinson
Journal article | 2005 | Journal of Virology
Most Epstein-Barr virus (EBV)-positive Burkitt's lymphomas (BLs) carry a wild-type EBV genome and express EBV nuclear antigen 1 (E..
Epstein-Barr virus-associated Burkitt lymphomagenesis selects for downregulation of the nuclear antigen EBNA2.
Gemma Kelly, Andrew Bell, Alan Rickinson
Journal article | 2002 | Nature Medicine
Epstein-Barr virus (EBV) is etiologically linked to endemic Burkitt lymphoma (BL), but its contribution to lymphomagenesis, versus..
Genetic analysis of the Epstein-Barr virus-coded leader protein EBNA-LP as a co-activator of EBNA2 function.
EM McCann, GL Kelly, AB Rickinson, AI Bell
Journal article | 2001 | Journal of General Virology
Co-operation between the Epstein-Barr virus (EBV)-coded leader protein EBNA-LP and the nuclear antigen EBNA2 appears to be critica..
Medical Biology (W.E.H.I.)
Doctor of Philosophy
The University of Birmingham